Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051909 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
A Phase 2 study of Alzheimers Disease, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 9
- Study locations
NCT00051909 is a Phase 2 study of Alzheimers Disease that has completed, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 5 states.
The verdict
NCT00051909, a Phase 2 study of Alzheimers Disease, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
Conditions Studied
Interventions
- DRUG LY451395
Study Locations (9)
Florida
- - Boca Raton
- - Fort Lauderdale
- - Miami Beach
California
- - Beverly Hills
- - Fresno
Oklahoma
- - Oklahoma City
- - Tulsa
Massachusetts
- - Boston
Texas
- - Wichita Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2002-11 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051909
The ClinicalTrials.gov registry entry for NCT00051909 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,060-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (95% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which LY451395 is the first listed.
NCT00051909 reports 9 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT00051909 about?
NCT00051909 is a clinical study titled "Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease". Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
What is the current status of trial NCT00051909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2002-11. Estimated completion is 2003-06.
What conditions does trial NCT00051909 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00051909?
The interventions under investigation include: LY451395 (DRUG).
Who is sponsoring clinical trial NCT00051909?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00051909 being conducted?
This trial has 9 study locations across California, Florida, Massachusetts, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
Open-label Extension Study in Participants With Early Alzheimer's Disease
RECRUITING · Phase 2
-
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
RECRUITING · Phase 2
-
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.